- [Resource Hub](/)
- [Field Guide](/?resource-type=field-guide#library)
- Building Reproducible Multi-Site Brain Tissue Atlases

# Building Reproducible Multi-Site Brain Tissue Atlases

The bottom line up front: Multi-site brain atlases require identical nuclei extraction results from every participating lab, every operator, every month. Manual FFPE protocols make this impossible -- deparaffinization timing, trituration force, and enzymatic digestion vary between technicians and between sites, producing batch effects that no computational correction can fully remove. The Singulator 200+ reduces the operator-dependent steps to 4 pipetting transfers within a sealed cartridge workflow, delivering replicate yields of 1.0 million and 1.0 million nuclei where semi-automated methods produce 1.5 million and 0.4 million. For brain atlases that depend on cross-site comparability, the instrument becomes the constant.

## The reproducibility problem at atlas scale

The ambitions behind brain atlas projects are staggering. The BRAIN Initiative Cell Census Network, the Human Cell Atlas brain effort, and institutional neurodegenerative disease consortia aim to profile millions of cells across dozens of brain regions, hundreds of donors, and multiple institutions. Each contributing site must produce data that integrates cleanly with data from every other site. A single lab with inconsistent nuclei extraction creates a downstream data quality problem that ripples through the entire atlas.

With fresh-frozen tissue, this challenge is difficult. With FFPE tissue -- where many of the most valuable retrospective brain collections are stored -- the challenge is compounded. FFPE processing adds deparaffinization, rehydration, and enzymatic digestion steps that vary dramatically with operator technique. Two technicians running the same published manual protocol in the same lab on consecutive days can produce yield differences of 3 to 4 fold. Now multiply that variability across five or ten sites, each with its own staff, reagent lots, and timing habits. The result is batch effects rooted in tissue processing, not in biology -- and they corrupt the very cellular diversity the atlas is trying to capture.

This guide covers how to use the Singulator 200+ to standardize brain FFPE nuclei extraction across multiple sites, eliminate the operator-dependent variability that manual protocols introduce, and build the processing consistency that atlas-quality data requires.

### TL;DR -- Multi-site brain atlas essentials

- Replicate consistency of 1.0M/1.0M nuclei eliminates the yield variability that drives batch effects

- Four pipetting steps leave almost nothing for operators to vary between sites

- No fume hood requirement means any lab with bench space can participate

- Sealed cartridge workflow removes deparaffinization as a source of site-to-site variability

- Track four QC metrics across sites: yield per mass, DV200, cell-type proportions, debris percentage

) -->

## Standardize brain FFPE processing across your consortium

Practical strategies for establishing, qualifying, and maintaining multi-site nuclei extraction consistency for brain atlas and consortium projects.

Eliminate operator-to-operator variability
Eliminate the operator as a source of variability

+

In manual FFPE nuclei extraction, the operator is the protocol. Deparaffinization depends on how long xylene incubates (some technicians set a timer for 20 minutes; others leave it overnight). Rehydration depends on how precisely the ethanol series is executed. Trituration depends on how hard and how many times someone pipettes. These are not minor procedural details -- they are the primary sources of variability in the nuclei output. A consortium with six sites and twelve technicians running manual protocols has twelve different versions of the "same" protocol.

### Where manual protocols break down

The PDAC FFPE application note quantified this problem directly. Semi-automated methods, which standardize the mechanical disruption step but still require manual deparaffinization, produced replicate yields of 1.5 million and 0.4 million nuclei -- a 3.75-fold difference from the same tissue type. That variability came from the operator-dependent steps that semi-automation does not address. Manual protocols, which have even more operator-dependent steps, show greater variability still.

For a brain atlas, this means the cluster composition in your snRNA-seq data may reflect who processed the tissue rather than the biology of the brain region. A site with aggressive trituration will destroy fragile neuronal nuclei and over-represent microglia. A site with gentle technique will preserve neurons but recover fewer total nuclei. Neither result is wrong in isolation, but when you merge the datasets, the cell-type proportions become incomparable.

STANDARDIZED CARTRIDGE PROCESSING

The Singulator 200+ two-cartridge workflow S200+ Only automates both deparaffinization ( GREEN FFPE cartridge) and nuclei isolation ( YELLOW NIC+ cartridge). The instrument controls mechanical force, enzymatic timing, and temperature. The operator loads the tissue, inserts the cartridges, and presses start. Four pipetting steps remain -- transferring tissue into the cartridge, moving processed output between cartridges, and collecting the final suspension. That is the entire scope of human variability in the protocol.

### What "operator-independent" actually means

No protocol is truly operator-independent. Someone still needs to section the block, weigh the tissue, and transfer the nuclei suspension. But reducing the operator-controlled steps from 28 (semi-automated) to 4 (Singulator 200+) compresses the window for human error by 86%. The replicate data reflects this: 1.0 million and 1.0 million nuclei from biological replicates, versus the 3.75-fold variability seen with semi-automated approaches. For a consortium, that consistency translates directly into cleaner data integration and fewer batch correction artifacts.

SECTIONING STILL MATTERS

The Singulator 200+ standardizes processing, not block preparation. Sites must still agree on section thickness (50 micrometer curls are the standard recommendation), minimum tissue mass (2 mg), and tissue handling before loading. Write these pre-instrument steps into the consortium SOP as precisely as the extraction protocol itself -- they are the remaining source of human variability.

Qualify new sites for your consortium
Qualify new sites before they process atlas tissue

+

Adding a new site to a multi-site brain atlas is not simply shipping an instrument and a protocol document. The site needs to demonstrate that its data meets the consortium's quality thresholds before any irreplaceable brain tissue goes through the workflow. A site qualification program prevents the worst-case scenario: discovering six months later that one site's data is unusable and cannot be reprocessed because the tissue is gone.

### Build a reference tissue panel

Select a tissue type with known processing characteristics -- the PDAC FFPE tissue used in the application note works well as a reference standard because its expected yields, cell-type proportions, and replicate consistency data are documented. Each new site processes the reference tissue on their Singulator 200+ and reports total nuclei yield, debris percentage, and DV200. Compare these values against the established benchmarks. A site that produces 1.0 million nuclei per curl from the reference tissue with less than 1% erythrocyte contamination is processing correctly. A site producing 400,000 nuclei from the same reference material needs protocol review before handling brain tissue.

REFERENCE TISSUE LOGISTICS

Distribute reference FFPE blocks from a single tissue source to all sites. Using the same source tissue eliminates biological variability from the qualification test, isolating instrument and operator performance. Purchase blocks in bulk from a tissue vendor or prepare them from a pooled source at the coordinating site.

### Qualification checklist

A practical site qualification process includes four stages. First, the site receives the instrument and completes the manufacturer's installation and training. Second, the site processes the reference tissue panel (three replicates minimum) and submits yield, DV200, and debris metrics. Third, the site processes a brain FFPE test sample and submits the same metrics plus a snRNA-seq run for cell-type proportion comparison. Fourth, the coordinating site reviews the data against consortium benchmarks and either qualifies the site or identifies specific steps that need correction.

This process typically takes two to three weeks. The investment is small compared to the cost of discovering that a site's data is an outlier after the tissue is consumed.

DO NOT SKIP BRAIN-SPECIFIC TESTING

Reference tissue from non-brain organs confirms that the instrument is working correctly, but brain FFPE has unique debris challenges -- myelin, lipids, and regional variability in cellularity. A site that passes qualification on PDAC tissue can still struggle with white matter regions from the corpus callosum. Include at least one brain FFPE section in the qualification panel to test the site's ability to handle brain-specific challenges.

Prevent batch effects at the source
Prevent batch effects before they reach your data

+

Computational batch correction is a well-developed field, and tools like Harmony, scVI, and BBKNN can reduce batch effects in merged datasets. But these methods work best when the batch effects are small and technical, not large and biological. When a batch effect originates in the nuclei extraction step -- one site's nuclei are mostly microglia because the prep destroyed neurons, while another site's nuclei preserve the expected cell-type diversity -- no algorithm can reconstruct the lost biology. The best batch correction strategy is upstream: eliminate the variability before it enters the data.

### The three sources of processing batch effects

In multi-site FFPE processing, batch effects come from three places. First, deparaffinization variability: how completely the paraffin is removed and how aggressively the solvents interact with the tissue. Manual xylene protocols are the largest contributor here. Second, mechanical disruption variability: the force applied during tissue dissociation, which determines which cell types survive. Third, enzymatic digestion variability: the duration and temperature of protease treatment, which affects both nuclei recovery and RNA quality.

The Singulator 200+ addresses all three. The GREEN FFPE cartridge handles deparaffinization with a proprietary safe solvent inside a sealed cartridge -- no xylene, no operator judgment about incubation time. The instrument controls the mechanical disruption parameters. And the YELLOW NIC+ cartridge manages enzymatic processing under controlled conditions. The result is that the three primary sources of processing batch effects are removed from operator control.

CARTRIDGE LOT TRACKING

Record the lot numbers for both GREEN and YELLOW cartridges used for each sample. In a multi-site atlas, cartridge lots are an important covariate. If a QC outlier appears, the lot number helps determine whether the issue is site-specific or lot-specific. Include lot tracking in your consortium metadata template alongside sample ID, brain region, donor demographics, and processing date.

### Reagent lot management across sites

Beyond cartridges, the buffers and reagents used for post-processing (resuspension, counting, concentration adjustment) can introduce variability. Coordinate reagent purchases across sites when possible -- buying from the same lot for all sites in a given processing window reduces one more source of technical variation. This is standard practice in clinical diagnostics and translates directly to atlas-scale research.

FUME HOOD BARRIER ELIMINATED

Manual FFPE protocols require fume hood access for xylene deparaffinization. This limits which labs can participate in a consortium -- some sites may lack fume hood availability, creating scheduling bottlenecks or excluding sites entirely. The Singulator 200+ uses a proprietary safe solvent inside the sealed GREEN cartridge, requiring no fume hood. Any lab with standard bench space can process FFPE samples, lowering the facility requirements for consortium participation.

Define QC gates for atlas inclusion
Define the QC metrics that gate atlas data inclusion

+

Not every sample that goes through the extraction workflow should end up in the atlas. A brain atlas is only as reliable as its weakest data point. Establishing clear, quantitative QC thresholds before processing begins protects the atlas from low-quality contributions that dilute the dataset. The QC framework should cover pre-sequencing metrics (assessed at the processing site) and post-sequencing metrics (assessed at the analysis hub).

### Pre-sequencing QC metrics

These metrics are assessed at the processing site immediately after nuclei extraction, before committing the sample to a sequencing run. They provide an early gate that saves sequencing costs and library prep reagents.

Nuclei yield per input mass: Track nuclei recovered per milligram of starting tissue. The Singulator 200+ typically produces over 1 million nuclei from a single 50-micrometer curl. Yields significantly below the expected range for a given brain region may indicate a tissue quality issue rather than an instrument problem. Cortical gray matter regions yield more nuclei per mass than white matter regions -- set region-specific benchmarks.

DV200 score: Run a DV200 quality check on a thin test section (separate from the section processed for nuclei). A DV200 above 50% is the target for high-quality atlas data. Between 30-50% , the data may be usable but with reduced gene detection per nucleus. Below 30% , consider whether the tissue quality warrants the sequencing cost. DV200 reflects the tissue quality, not the extraction performance -- but tracking it across sites ensures that all sites are working with tissue of comparable starting quality.

DEBRIS THRESHOLD

Assess debris content by visual inspection under a microscope or by quantifying the fraction of events below the nuclei size gate on a Moxi V or similar sizing instrument. Brain tissue inherently produces more lipid and myelin debris than other organs. Set a debris threshold that accounts for this -- a cortical sample with 20% debris-sized events may be acceptable, while the same percentage from a visceral organ would raise concerns. The built-in filters in the Singulator 200+ cartridges reduce debris compared to manual methods, but brain tissue will always produce more debris than liver or kidney.

### Post-sequencing QC metrics

After sequencing, the analysis hub should assess gene detection per nucleus, cell-type proportions relative to expected regional composition, and the fraction of reads mapping to mitochondrial genes (high mitochondrial read fractions suggest damaged nuclei). Samples that fail post-sequencing QC should be flagged but not silently dropped -- track failures to identify whether they cluster by site, by brain region, by block age, or by processing date.

QC FAILURE TRIAGE

When a sample fails QC, determine whether the failure reflects tissue quality (block age, fixation conditions, PMI) or processing quality (instrument, operator, or site-specific issue). If multiple samples from the same site fail while other sites pass, the problem is likely site-specific and warrants a requalification. If failures cluster by block age or donor cohort, the tissue source is the issue, and no protocol change will fix it.

Scale processing for multi-year atlas timelines
Scale processing across multi-year atlas timelines

+

Brain atlas projects do not finish in a semester. The BRAIN Initiative Cell Census Network spans years. Longitudinal neurodegenerative disease studies process samples from cohorts enrolled a decade ago. A consortium may process its first batch of samples today and its last batch three years from now. Over that timeline, technicians leave and are replaced, reagent formulations may change, and instrument firmware updates may be released. The processing protocol must produce comparable results across that entire span.

### Personnel turnover and training

Manual protocols are vulnerable to personnel changes because the technique lives in the hands of the person running the protocol. When a trained technician leaves and a new one takes over, the "same" protocol produces different results until the new technician develops comparable skill. This problem compounds across sites -- each personnel change at each site introduces a new batch effect.

The Singulator 200+ compresses the skill-dependent portion of the workflow to four transfer steps. Training a new operator takes hours, not weeks. The instrument delivers the same mechanical force and enzymatic timing regardless of who loaded the cartridges. For multi-year atlas projects, this means personnel turnover does not require a requalification cycle -- the instrument performance is independent of operator experience.

THROUGHPUT FOR ATLAS SCALE

Each Singulator 200+ run takes approximately 60 minutes with less than 5 minutes of hands-on time. One technician can stagger 6 to 8 runs per day. For a consortium site responsible for 200 samples per year, that is roughly 25 to 33 processing days -- achievable within a standard work schedule alongside other responsibilities. The walk-away processing time means the operator does not need to stand at the instrument for the entire run.

### Longitudinal consistency across years

A well-designed atlas produces data over years, and the samples processed in year three must integrate seamlessly with the samples processed in year one. Manual protocols drift over time as small procedural adjustments accumulate -- a new brand of xylene, a slightly different incubation time, a technician who develops a preference for firmer trituration. These drifts are difficult to detect in real time and manifest only when year-one and year-three data are merged.

The Singulator 200+ eliminates most of these drift vectors because the processing parameters are defined by the instrument and the cartridges, not by operator habits. As long as the cartridges and firmware remain consistent, the output from a sample processed in 2026 is comparable to a sample processed in 2029. Track firmware versions and cartridge lot numbers as consortium metadata to identify any changes that coincide with QC shifts.

METADATA STANDARDS FOR ATLAS PROJECTS

Every sample processed for the atlas should carry a metadata record that includes: donor demographics, brain region, block age, PMI, fixation duration (if known), section thickness, tissue mass, cartridge lot numbers (both GREEN and YELLOW ), instrument serial number, firmware version, processing date, operator ID, nuclei yield, DV200, and debris assessment. This metadata table becomes the backbone for troubleshooting QC outliers and for batch effect analysis in the merged dataset.

## Troubleshooting multi-site atlas challenges

Problem: One site consistently produces lower nuclei yields than other sites from the same reference tissue
Solution: Verify the site's tissue handling before instrument loading. Common causes include inaccurate tissue weighing (using less than 2 mg input), inadequate tissue transfer into the cartridge (tissue sticking to the tube wall or forceps), or using curls thinner than the recommended 50 micrometers. Have the site process three replicates of the reference tissue with the coordinating site observing (via video call if remote) to identify the specific step where tissue is being lost. The issue is almost always pre-instrument, not instrument-related.

Problem: Cell-type proportions differ between sites even when processing the same brain region
Solution: First, confirm the sites are processing tissue from the same brain region and donor cohort -- regional and donor variability in cell-type composition is biological, not technical. If the tissue source is identical and the proportions still differ, check post-processing steps: nuclei counting method, concentration adjustment, and the sequencing library prep protocol. On the Singulator 200+ with the same cartridge workflow, the nuclei extraction itself should produce consistent cell-type distributions. Variability more often enters at the library prep and sequencing stage.

Problem: Batch effects appear in merged atlas data despite standardized extraction
Solution: Standardized extraction reduces but may not eliminate all batch effects. Remaining batch effects often stem from differences in sequencing platform, library prep chemistry, read depth, or computational analysis pipeline rather than tissue processing. Check whether the batch effect correlates with processing site (extraction issue), sequencing run (platform issue), or analysis version (pipeline issue). Run the same libraries on two sequencing instruments to test whether the batch effect is sequencer-dependent. For atlas projects, standardize the library prep and sequencing protocols with the same rigor as the extraction protocol.

Problem: A consortium site wants to join but lacks experience with FFPE nuclei extraction
Solution: The Singulator 200+ was designed for exactly this scenario. The instrument automates the technically demanding steps, and the four manual pipetting transfers require standard bench skills rather than FFPE-specific expertise. New sites should complete the qualification process described above: install the instrument, process reference tissue, process brain FFPE test samples, and submit QC metrics for coordinating site review. A site with no prior FFPE experience can be qualified within two to three weeks. No fume hood is required, which eliminates the most common facility barrier for new sites.

## Frequently asked questions

Can different sites use the Singulator 200+ with the same protocol and get comparable results?

Yes. The Singulator 200+ uses sealed, pre-loaded cartridges that standardize the mechanical and enzymatic processing parameters. The instrument applies the same force, temperature, and timing regardless of which site operates it. Published replicate data shows 1.0 million and 1.0 million nuclei across biological replicates, compared to 1.5 million and 0.4 million with semi-automated methods. The 4 pipetting steps leave almost nothing for operators to vary between sites.

How does the Singulator 200+ reduce batch effects in multi-site brain atlas projects?

Batch effects in atlas projects stem from variable tissue processing, not variable biology. Manual FFPE protocols introduce operator-dependent differences in deparaffinization timing, trituration force, and enzymatic digestion duration. The Singulator 200+ eliminates these variables by automating the complete workflow within sealed cartridges. The same cartridge protocol runs identically at every site, reducing the technical variability that computational batch correction cannot fully remove.

What QC metrics should consortium sites track to verify processing consistency?

Track four metrics across sites: total nuclei yield per input mass, DV200 score from a parallel test section, cell-type proportions from snRNA-seq clustering, and debris percentage in the nuclei suspension. Yield and DV200 are measured before sequencing and flag processing or tissue quality issues immediately. Cell-type proportions and debris levels confirm that the extraction preserved the expected biological diversity. Sites that consistently fall outside established ranges need protocol review.

Does the Singulator 200+ require a fume hood for FFPE processing?

No. The Singulator 200+ GREEN FFPE cartridge uses a proprietary safe solvent for deparaffinization that does not require a fume hood. Manual FFPE protocols use toxic xylene or CitriSolv and require fume hood access, which limits which sites can participate in a consortium. Eliminating the fume hood requirement means any lab with bench space can join a multi-site atlas project.

How many brain FFPE samples can one Singulator 200+ process in a day for atlas-scale projects?

Each run takes approximately 60 minutes with less than 5 minutes of hands-on time. A single operator can process 6 to 8 samples per day by staggering runs. The S200+ handles 1 to 2 samples per run. For atlas projects requiring hundreds or thousands of samples, the walk-away processing time means one technician can manage the instrument while handling other tasks between runs.

### Key takeaway

Brain atlases are built on the assumption that data from different sites, operators, and time points can be merged into a unified resource. Manual FFPE protocols violate that assumption at the nuclei extraction step, introducing operator-dependent variability that no computational correction can fully undo. The Singulator 200+ makes the instrument the constant -- delivering replicate-level consistency across sites, across operators, and across the multi-year timelines that atlas projects demand. For consortia building reproducible, multi-million-cell brain tissue atlases from FFPE archives, standardized automated extraction is the foundation everything else depends on.

[Back to all resources](/#library)
## Similar resources
[Field Guide](/resources/brain-tissue-complexity-myelin-lipids-neuronal-nuclei/) Singulator 200+ 2026
### Overcoming Brain Tissue Complexity: Myelin, Lipids, and Fragile Neuronal Nuclei

Brain FFPE tissue creates unique nuclei isolation challenges. Myelin debris, lipid contamination, and fragile neuronal nuclei require controlled automated processing to preserve cell-type diversity for single-nucleus sequencing.
[Read Field Guide](/resources/brain-tissue-complexity-myelin-lipids-neuronal-nuclei/) [Field Guide](/resources/brain-tumor-ffpe-surgical-resection-single-cell/) Singulator 200+ 2026
### Brain Tumor FFPE Processing: From Surgical Resection to Single-Nucleus Insights

Process brain tumor FFPE from surgical resections on the Singulator 200+. Preserve cancer cells and immune populations for snRNA-seq and spatial analysis.
[Read Field Guide](/resources/brain-tumor-ffpe-surgical-resection-single-cell/) [Ebook](/resources/cold-case-files-neuroscience-ffpe/) Singulator 200+ 2026
### Cold Case Files:The Brain's Embedded Evidence

How the Singulator 200+ preserves fragile neuronal nuclei from irreplaceable postmortem brain tissue. Automated FFPE processing for Alzheimer's, brain tumors, and brain atlases.
[Read Ebook](/resources/cold-case-files-neuroscience-ffpe/) [Field Guide](/resources/ffpe-neurodegenerative-disease-research-singulator/) Singulator 200+ 2026
### FFPE Nuclei Extraction for Neurodegenerative Disease Research

Extract nuclei from FFPE brain tissue for Alzheimer's, Parkinson's, and Lewy body research. Longitudinal cohorts, cell-type preservation, and disease staging on the Singulator 200+.
[Read Field Guide](/resources/ffpe-neurodegenerative-disease-research-singulator/) [Field Guide](/resources/integrating-snrna-seq-spatial-transcriptomics-brain-ffpe/) Singulator 200+ 2026
### Integrating snRNA-seq with spatial transcriptomics for brain mapping

Pair spatial transcriptomics with snRNA-seq from the same FFPE brain block. Block allocation, platform selection, and nuclei quality for multi-omic brain studies.
[Read Field Guide](/resources/integrating-snrna-seq-spatial-transcriptomics-brain-ffpe/) [Field Guide](/resources/maximizing-limited-brain-tissue-sections-ffpe/) Singulator 200+ 2026
### Maximizing Results from Limited Brain Tissue Sections

Get high-quality nuclei from limited postmortem brain FFPE sections. Process NIH biobank allocations, hospital archives, and surgical specimens on the Singulator 200+.
[Read Field Guide](/resources/maximizing-limited-brain-tissue-sections-ffpe/) [Field Guide](/resources/navigating-postmortem-brain-tissue-ffpe-genomics/) Singulator 200+ 2026
### Navigating postmortem brain tissue for FFPE genomics

Practical guide to postmortem brain FFPE challenges: necropsy timing, fixation variability, biobank sourcing, myelin debris, and how the Singulator 200+ standardizes nuclei extraction.
[Read Field Guide](/resources/navigating-postmortem-brain-tissue-ffpe-genomics/) [Ebook](/resources/tissue-dissociation-protocol-guide/) Singulator 100 Singulator 200 Singulator 200+ 2026
### Tissue Dissociation Guide

The most comprehensive tissue dissociation reference available. Interactive protocols for single-cell isolation and nuclei extraction across 57+ tissue types with community and Singulator-optimized methods.
[Read Ebook](/resources/tissue-dissociation-protocol-guide/) [Blog](/resources/cold-case-closed-brain-atlas/) Singulator 200+ 2026
### Cold Case - Part 5: Case Closed

Brain atlases are being built. Archival tissue is finally talking. How standardized nuclei extraction and platform-agnostic analysis are solving neuroscience's oldest cold cases.
[Read Blog](/resources/cold-case-closed-brain-atlas/) [Blog](/resources/cold-case-contaminated-evidence-brain-tissue/) Singulator 200+ 2026
### Cold Case - Part 2: Contaminated Evidence

Manual extraction of nuclei from FFPE brain tissue destroys 50 to 60 percent of starting material. Fragile neurons die first, leaving biased results. Here is what goes wrong.
[Read Blog](/resources/cold-case-contaminated-evidence-brain-tissue/) [Blog](/resources/cold-case-files-brain-tissue-evidence/) Singulator 200+ 2026
### Cold Case - Part 1: The Cold Case Files

Millions of FFPE brain tissue blocks sit in biobanks worldwide, holding decades of evidence about Alzheimer's, Parkinson's, and neurodegenerative diseases. What if we could reopen these cases?
[Read Blog](/resources/cold-case-files-brain-tissue-evidence/) [Blog](/resources/cold-case-forensic-lab-singulator-200-plus/) Singulator 200+ 2026
### Cold Case - Part 4: The Forensic Lab

Manual FFPE processing destroys fragile neuronal nuclei and produces variable results. The Singulator 200+ automates the workflow with a two-cartridge system that delivers consistent, operator-independent results from irreplaceable brain tissue.
[Read Blog](/resources/cold-case-forensic-lab-singulator-200-plus/)